Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02817204
Other study ID # HVD001
Secondary ID
Status Recruiting
Phase Phase 3
First received June 22, 2016
Last updated April 23, 2017
Start date May 2016
Est. completion date July 30, 2017

Study information

Verified date April 2017
Source First Affiliated Hospital, Sun Yat-Sen University
Contact Jun Tao, PhD
Phone +8613922191609
Email taojungz123@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effect of aerobic exercise training on microcirculation rarefaction in Chinese young male primary hypertensive patients stage 1. Hypertension is one of the most common world-wide chronic diseases, and it is showing a growing younger trend, which with mild blood pressure elevated would not be diagnose in time until blood pressure raises up or symptoms show up (Mild blood pressure indicates blood pressures ranging from 140 to 159 mmHg systolic and/or 90 to 99 mmHg diastolic). However, cumulative evidences prove that microvascular rarefaction exist in hypertensive patients with even primary hypertension stage 1. Exercise prescription is gathering great importance in preventive health. Aerobic exercise, especially, has the potential to diminish blood pressure values, and aerobic exercise can promote angiogenesis in coronary heart disease. Notch signaling plays an important role in vascular formation and maintenance. However, there is no prospective, randomized, controlled, clinic trial to investigate the effect of exercise on microcirculation rarefaction in hypertension. In summary, investigators propose a hypothesis that aerobic exercise might not only have a blood pressure lowing effect but also improve microcirculation rarefaction in Chinese male adults with primary mild hypertension. For that, subjects will be enrolled for one pre-intervention cardiopulmonary exercise test (CPET) and then randomized in aerobic exercise intervention group and control group (only health education), the intervention will be carried out by Cycle Ergometer, the protocol consists of 3 sessions a day: 3 minutes Warm up, 45 minutes Resistance Exercise at 75% of HRmax; 10 minutes Recovery. Thus 58 minutes a day and 5 days a week (about 2000kcal) and 12 weeks in total. Prior and after all intervention sessions (12 weeks), nail fold capillary microscopy and retinal capillary Optical Coherence Tomography(OCT) angiography will be assessed, as well as 24h blood pressure monitoring, echocardiography, forearm blood flow and reactive hyperemia by venous occlusion plethysmography (FMD), PWV, central arterial pressure, RHI with Endopat, also the quantification of endothelial progenistor cells(EPCs) separated from peripheral blood.


Description:

Hypertension is one of the most common world-wide chronic diseases, and it is showing a growing younger trend, which with mild blood pressure elevated would not be diagnose in time until blood pressure raises up or symptoms show up (Mild blood pressure indicates blood pressures ranging from 140 to 159 mmHg systolic and/or 90 to 99 mmHg diastolic). However, cumulative evidences prove that microvascular rarefaction exist in hypertensive patients with even primary hypertension stage 1. Exercise prescription is gathering great importance in preventive health. Aerobic exercise, especially, has the potential to diminish blood pressure values, and aerobic exercise can promote angiogenesis in coronary heart disease. Notch signaling plays an important role in vascular formation and maintenance. However, there is no prospective, randomized, controlled, clinic trial to investigate the effect of exercise on microcirculation rarefaction in hypertension. In summary, investigators propose a hypothesis that aerobic exercise might not only have a blood pressure lowing effect but also improve microcirculation rarefaction in Chinese male adults with primary mild hypertension. For that, subjects will be enrolled for one pre-intervention cardiopulmonary exercise test (CPET) and then randomized in aerobic exercise intervention group and control group (only health education), the intervention will be carried out by Cycle Ergometer, the protocol consists of 3 sessions a day: 3 minutes Warm up, 45 minutes Resistance Exercise at 75% of HRmax; 10 minutes Recovery. Thus 58 minutes a day and 5 days a week (about 2000kcal) and 12 weeks in total. Prior and after all intervention sessions (12 weeks), nail fold capillary microscopy and retinal capillary Optical Coherence Tomography(OCT) angiography will be assessed, as well as 24h blood pressure monitoring, echocardiography, forearm blood Flow Mediated Diastolic function(FMD), Plus Wave Velocity(PWV), Reactive Hyperemia Index(RHI) with Endopat, also the quantification of endothelial progenistor cells(EPCs) separated from peripheral blood.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 30, 2017
Est. primary completion date July 30, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 25 Years to 40 Years
Eligibility Inclusion Criteria:

- Subjects range from 18 to 40 years old.

- male

- Blood pressure is primary hypertension stage I(systolic blood pressure 140 to 159 mmHg and/or diastolic blood pressure 90 to 99 mmHg).

- Able to participate in exercise

- No regular physically active in the last 4 months

- Provide informed consent and willingness to cooperate with the study protocol

Exclusion Criteria:

- Less than 18 years old or above 40 years old

- Secondary hypertension.

- Females

- Systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic renal failure, tuberculosis, and autoimmune diseases

- Medical history of cardiovascular disease: acute myocardial infarct, stable angina, unstable angina, heart failure, atrial fibrillation, atrioventricular blockade, peripheral vascular disease or cerebrovascular accident

- Patients who are unfavorable of long-term follow-up or poor compliance

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Aerobic Exercise
Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
Health Education
Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol

Locations

Country Name City State
China First Affiliated Hospital,Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
First Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retinal capillary density with Quantitative Optical Coherence Tomography(OCT) angiography(OCT)) Change from Baseline retinal capillary density at 12 weeks
Primary Nail fold capillary numbers per square millimeter( /mm²) Change from Baseline nail fold capillary density at 12 weeks
Secondary 24 hours ambulatory blood pressure (ABP) in millimeters of mercury(mmHg) Change from Baseline Systolic Blood Pressure and Diastolic Blood Pressure at 12 weeks
Secondary Flow-mediated Dilation(FMD) in % The percentage change in brachial artery diameter from baseline Change from Baseline percentage at 12 weeks
Secondary Reactive Hyperemia Index(RHI) in the ratio of the average amplitude of the PAT signal RHI was measured using the RH-PAT system (EndoPAT):A blood pressure cuff was placed on 1 upper arm with the contralateral arm serving as a control. A PAT probe was placed on 1 finger of each hand. After a 5-minute equilibration period, the cuff was inflated to 60 mm Hg above the systolic pressure or to 200 mm Hg for 5 minutes, then deflated to induce reactive hyperemia. Change from Baseline ratio at 12 weeks
Secondary Abilities of tube formation of endothelial progenistor cells(EPCs) in tube numbers Tube formation ability of EPCs was evaluated by counting tube numbers. Images of tube morphology were taken under the inverted phase contrast microscope. Change from Baseline tube numbers at 12 weeks
Secondary Left Ventricular End-diastolic Volume (LVEDV) in milliliter(ml) Change from Baseline volume at 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT00573742 - Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients N/A
Recruiting NCT06208072 - The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone. N/A
Recruiting NCT06049862 - The Effectiveness of "MaRiTensi" in Increasing Self-Care and Blood Pressure Control: Randomized Controlled Trial N/A
Completed NCT00819104 - A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components Phase 4
Not yet recruiting NCT06091176 - Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension N/A
Recruiting NCT01742702 - HaemoDYNAMICs in Primary and Secondary Hypertension
Completed NCT00794885 - China Stroke Primary Prevention Trial Phase 4
Active, not recruiting NCT04381520 - Heat-sensitive Moxibustion Self-administration in Patients in the Community With Primary Hypertension: Protocol for a Multi-center, Pragmatic, Non-randomized Trial N/A
Completed NCT00865501 - Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease Phase 3
Active, not recruiting NCT04788563 - A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community N/A
Completed NCT02184858 - Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension Phase 4
Completed NCT03105687 - Effectiveness of SMS Reminders of Blood Pressure-lowering Drugs Intake N/A
Completed NCT01392534 - Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting N/A
Active, not recruiting NCT03015311 - Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients N/A
Enrolling by invitation NCT03470974 - The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension N/A
Active, not recruiting NCT01844570 - Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research N/A
Completed NCT01241487 - A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy Phase 4
Completed NCT00882947 - Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH) Phase 4
Active, not recruiting NCT03310684 - Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)
Not yet recruiting NCT02901704 - Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension Phase 3